Latest Information Update: 15 Feb 1996
At a glance
- Originator Merck & Co
- Class Antibacterials; Macrolides
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 15 Feb 1996 No-Development-Reported for Bacterial infections in USA (PO)